Allogeneic Hematopoietic Stem Cell Transplantation for Children With Acute Lymphoblastic Leukemia: Shifting Indications in the Era of Immunotherapy
Open Access
- 23 December 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 9, 782785
Abstract
Pediatric acute lymphoblastic leukemia generally carries a good prognosis, and most children will be cured and become long-term survivors. However, a portion of children will harbor high-risk features at the time of diagnosis, have a poor response to upfront therapy, or suffer relapse necessitating more intensive therapy, which may include allogeneic hematopoietic stem cell transplant (HSCT). Recent advances in risk stratification, improved detection and incorporation of minimal residual disease (MRD), and intensification of upfront treatment have changed the indications for HSCT over time. For children in first complete remission, HSCT is generally reserved for those with the highest risk of relapse. These include patients with unfavorable features/cytogenetics who also have a poor response to induction and consolidation chemotherapy, usually reflected by residual blasts after prednisone or by detectable MRD at pre-defined time points. In the relapsed setting, children with first relapse of B-cell ALL are further stratified for HSCT depending on the time and site of relapse, while all patients with T-cell ALL are generally consolidated with HSCT. Alternatives to HSCT have also emerged over the last decade including immunotherapy and chimeric antigen receptor (CAR) T-cell therapy. These novel agents may spare toxicity while attempting to achieve MRD-negative remission in the most refractory cases and serve as a bridge to HSCT. In some situations, these emerging therapies can indeed be curative for some children with relapsed or resistant disease, thus, obviating the need for HSCT. In this review, we seek to summarize the role of HSCT in the current era of immunotherapy.Keywords
This publication has 79 references indexed in Scilit:
- Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup studyThe Lancet Oncology, 2012
- Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2012
- The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemiaBlood Reviews, 2012
- Outcomes after Induction Failure in Childhood Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2012
- Analysis of the Role of Hematopoietic Stem-Cell Transplantation in Infants With Acute Lymphoblastic Leukemia in First Remission and MLL Gene Rearrangements: A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2011
- Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trialThe Lancet, 2010
- First isolated extramedullary relapse in children with B-cell precursor acute lymphoblastic leukaemia: Results of the Cooprall-97 studyEuropean Journal of Cancer, 2008
- Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group studyLeukemia, 2008
- Reinduction Platform for Children With First Marrow Relapse of Acute Lymphoblastic Leukemia: A Children's Oncology Group StudyJournal of Clinical Oncology, 2008
- Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group studyBlood, 2008